Nikhil C. Munshi MD
Adjunct Associate Professor, Hematology & Medical Oncology
72 E. Concord Street nikhil.munshi@va.gov
Sections
Hematology & Medical Oncology
Biography
Dr. Nikhil Munshi received his medical degree from Maharaja Sayajirao University, followed by an internship and residency in internal medicine at Shri Sayaji General Hospital and Maharaja University in India. He then completed an oncology fellowship at Johns Hopkins Ocology Center, and an hematology/oncology fellowhip at Indiana University Medical Center. Dr. Munshi is currently professor of medicine in the Department of Medicine at Harvard Medical School, as well as an attending physician at VA Boston Healthcare System and Dana-Farber Cancer Institute.
A diplomate of American Board of Internal Medicine, Dr. Munshi is also on the Board of Directors of the International Myeloma Society. He is a member of numerous professional associations including the Indian Medical Association, Physician’s Association of India, Indian Association of Clinical Oncology, American Medical Association, American Society of Clinical Oncology, and the American Society of Hematology, among others. In addition, he is on the editorial board of Clinical Lymphoma and Myeloma and Personalized Medicine in Oncology and is an ad hoc reviewer for numerous professional journals.
Dr. Munshi’s current laboratory research and clinical activities specialize in plasma cell disorders with a focus on understanding oncogenomic changes in myeloma and developing a translational research programs in myeloma. He has also established a Myeloma Initiative at Veterans Administration Hospitals, a comprehensive program bringing together, for the first time, all major VA hospitals across the country to focus on cutting-edge joint clinical studies.
Education
MBBS, Maharaja Sayajirao University
MD, Maharaja Sayajirao University
Publications
Maisano D, Wang T, Kulp SB, Favasuli VK, Tong Y, Cumerlato M, Li C, Barello F, Turi M, Rampa P, Parisi RA, Garbicz F, Ladisa F, Giorgetti G, Chakraborty C, Vreux L, Sangiorgio V, Sarotto I, Aktas Samur A, Samur MK, Carrasco RD, Fulciniti M, Cameron MD, Anderson KC, Gulla A, Childs-Disney J, Disney MD, Morelli E, Munshi NC. A first-in-class RNA degrader reduces c-MYC expression and myeloma cell survival in preclinical models. Blood. 2026 Jul 29. PMID: 42526890.
Published on 7/21/2026Lazzaro A, Nannini K, Yildirim C, Huhmann L, Culnan JM, Corrigan JK, Elbers D, Do NV, Brophy MT, Munshi NC, Fillmore NR, Edwards CV. Evolution of Real-World Front-Line Treatment Patterns in Multiple Myeloma. Blood Adv. 2026 Jul 21. PMID: 42480210.
Published on 7/15/2026Wan X, Du T, Fang T, Wang M, Ray A, Wen K, Musa MA, Garbicz F, Carrasco RD, Samur AA, Fulciniti M, Talluri S, Song Y, Munshi NC, Anderson KC. The role of RAD23A in DNA repair and proteasome-dependent protein degradation in multiple myeloma. Blood Cancer J. 2026 Jul 15. PMID: 42457667.
Published on 7/8/2026Guerrera ML, Liu X, Tsakmaklis N, Peachey AL, Kofides A, Hatcher J, Ramirez Gamero A, Guijosa A, Yang G, Sun H, Liu S, Patterson CJ, Meid K, Flynn C, Carrasco RD, Branagan AR, Sarosiek SR, Castillo JJ, Anderson KC, Munshi N, Treon SP, Hunter ZR. WNK2 oncogenicity revealed by the discovery and functional characterization of novel gene isoforms in MYD88 mutated Waldenström's Macroglobulinemia. Blood Cancer J. 2026 Jul 08. PMID: 42420257.
Published on 7/2/2026Paiva B, Manrique I, Thompson E, Campbell TB, Guerrero C, Martin N, Anderson LD, Berdeja JG, Lonial S, Raje NS, Lin Y, Moreau P, San-Miguel JF, Munshi NC, Kaiser S. Idecabtagene vicleucel and endogenous T-cell phenotypes linked to progression-free survival in relapsed multiple myeloma. Hemasphere. 2026 Jul; 10(7):e70423. PMID: 42396130.
Published on 6/5/2026Ladisa F, Morelli E, Soncini D, Garibotto M, Munshi NC, Fulciniti M, Cea M. CRISPR application in hematological disorders: from bench to bedside. Blood Adv. 2026 Jun 05. PMID: 42263664.
Published on 6/3/2026Schavgoulidze A, Cui J, Encinas J, Favasuli VK, Talluri S, Mahéo S, Cerutti C, Shammas MA, Primo D, Vicente C, Larrayoz M, Martínez-Climent JA, Anderson KC, Aktas Samur A, Samur MK, Avet-Loiseau H, Corre J, Munshi NC, Fulciniti M. PKMYT1 is a Targetable Vulnerability in del(17p) High-Risk Multiple Myeloma. Blood. 2026 Jun 03. PMID: 42237635.
Published on 5/28/2026Nadeem O, Redd RA, Barth PM, Bayliss TJ, Laubach JP, Bianchi G, Mo CC, Reagan JL, Midha S, Sperling AS, Liu Y, Hartley-Brown MA, Chuma MP, Nicholson T, Benjamin EJ, Distaso A, Regan E, Hof AMV, Dahill AJ, Goldbaum R, Mohammadi K, Lewis A, Poda R, Munshi NC, Anderson KC, Ghobrial IM, Richardson PG. A phase I/II study of twice-weekly ixazomib plus pomalidomide and dexamethasone in relapsed and refractory multiple myeloma. Haematologica. 2026 May 28. PMID: 42206445.
Published on 5/27/2026Sperling AS, Derman BA, Nikiforow S, Alonso A, Ikegawa S, Orwitz N, Quinn DS, Pearson D, Bu D, Milanez-Almeida P, Mataraza J, Nadeem O, Liegel J, D'Souza A, Charles A, Credi M, Ritz J, Jakubowiak AJ, De Vita S, Munshi NC. Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma. Sci Transl Med. 2026 May 27; 18(851):eadx1799. PMID: 42202046.
Published on 5/14/2026Du T, Fang T, Pillai S, Ray A, Wang M, Wan X, Wen K, Liu Y, Xu J, Musa MA, Liu X, Fulciniti M, Munshi NC, Garbicz F, Carrasco RD, Yao Y, Zhang Z, Song Y, Anderson KC. Proteasome subunit PSMD1 is a key therapeutic target in multiple myeloma. Blood. 2026 May 14; 147(20):2344-2357. PMID: 41632828.